12 May 2026
12 May 2026
Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands.
Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.
The FDA approval was based on data from the multi-centre, open-label Phase II eNRGy clinical trial.
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
CTTQ will manage importation, distribution, hospital access, and all promotional and non-promotional activities for bepirovirsen.
A spike in facility sales to outsourcing companies points to an industry need for greater flexibility.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
